Abstract: OBJECTIVE To explore the research status and application prospects of physiologically-based pharmacokinetic (PBPK) models in therapeutic antibodies. METHODS Referring to the relevant literature at home and abroad in recent years, this paper outlined the pharmacokinetics(PK) of antibodies and the influencing factors of PK, summarized the currently available PBPK models for therapeutic antibodies, and analyzed the establishment and parameter optimization of PBPK models under different scenarios, as well as important physiological processes to be considered, such as neonatal Fc receptor(FcRn) mediated recycling and target-mediated drug disposition(TMDD). RESULTS Due to their special structures and biological activities, therapeutic antibodies had significant differences in absorption, distribution, metabolism and excretion in vivo compared with small molecule drugs, and had apparent clinical advantages in the field of molecular targeted therapy. Scientifically and rationally applying the PBPK models might help predict the PK of therapeutic antibodies in animals or humans, which was essential for developing safe and effective therapeutic regimens. CONCLUSION PBPK modeling has a broad application prospect in therapeutic antibodies. It is necessary to utilize appropriate model structures based on actual conditions and constantly improve the prediction performance of PBPK models through model verification and parameter optimization.